Diamyd Medical
Diamyd Medical is a Swedish biopharmaceutical company focused on precision medicine for type 1 diabetes. Its core work centers on developing antigen-specific immunotherapies, led by the investigational product Diamyd® (rhGAD65/alum), alongside in-house manufacturing of the recombinant GAD65 active ingredient in Umeå.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInvestigational drug candidates and clinical programs for type 1 diabetes.
Internal production of recombinant GAD65 active pharmaceutical ingredient.
Precision medicine research, biomarker strategy, and supporting R&D activities.
Customers
Diamyd Medical does not sell a broad commercial product portfolio; its main end users are patients with type 1 diabetes, accessed through clinical trials, future prescribing physicians, and healthcare systems. In the nearer term, its direct counterparties are clinical trial sites, research collaborators, and potential licensing or commercialization partners. The company’s manufacturing capability also creates a potential customer base for external biomanufacturing projects.
Patients in clinical studies who receive or are evaluated for Diamyd® to preserve endogenous insulin production.
Hospitals and clinics that administer trials, collect samples, and generate the clinical data needed for approval.
Potential partners that may license Diamyd® or support commercialization in selected markets.
Third parties that may use the Umeå facility for biological compound production.
Strategy
Diamyd Medical’s strategy is built around advancing Diamyd® through registrational clinical development and using precision medicine to target genetically defined patient groups. The company also emphasizes patent protection, regulatory designations, and in-house manufacturing to support future commercialization and control supply. Partnerships with patient organizations and potential licensing arrangements are part of the route to market.
The Phase 3 program is the key clinical and regulatory value driver.
Genetically defined patient selection can improve clinical differentiation and commercial focus.
Owning API production reduces dependence on external suppliers and supports scalability.
Patent coverage underpins future licensing and commercialization economics.
Geography
Diamyd Medical is headquartered in Stockholm and operates a manufacturing facility in Umeå, Sweden. Its clinical development work spans the United States and Europe, and its patent estate extends across multiple regions including Europe, the US, Japan, South Korea, China, Canada, and others. Geography matters because the company’s trial execution, regulatory pathway, and future commercialization opportunities are tied to these markets.
Risks
Diamyd Medical faces the typical risks of a clinical-stage biotech company: trial failure, regulatory setbacks, and uncertainty around commercialization. Its value also depends on intellectual property protection, partner execution, manufacturing reliability, and continued access to financing while development programs remain pre-commercial.
- Drug development failureImpact: CriticalLikelihood: Medium
The company depends on positive clinical data from DIAGNODE-3 and related studies.
Exposure: Diamyd® and the Phase 3 program
- Regulatory approval riskImpact: HighLikelihood: Medium
Approval depends on FDA and other authority decisions, which can change timelines or requirements.
Exposure: BLA and future market authorization
- Intellectual property riskImpact: HighLikelihood: Medium
Patent scope, validity, and enforceability are central to future commercialization and licensing.
Exposure: GAD65 and precision medicine patents
- Financing riskImpact: HighLikelihood: Medium
Clinical-stage biotech companies often require external capital before revenues are established.
Exposure: Ongoing R&D and trial funding
- Manufacturing and supply-chain riskImpact: MediumLikelihood: Low
The company relies on successful scale-up and reliable GMP production of recombinant GAD65.
Exposure: Umeå facility and API supply
Accounting
Judgemental itemsClinical development costs are expensed as incurred, so trial activity directly affects reported earnings.
Impact: Timing of DIAGNODE-3 and other studies drives expense volatility
Grant income is recognized only when conditions are met, which can shift revenue timing.
Impact: Can create uneven recognition across periods
The Umeå facility and other leased assets may create right-of-use assets and lease liabilities.
Impact: Affects EBITDA-like measures, leverage, and depreciation/interest split
Performance share rights and options create non-cash personnel expense and dilution.
Impact: Impacts operating costs and equity dilution
Operations and clinical activity span multiple currencies, creating FX exposure.
Impact: Can affect reported profit and balance sheet values
Similar listed companies
Publicly listed companies with a comparable business focus.
Dyadic International, Inc
DYAI · Biological Products, (No Diagnostic Substances)
Dyadic International is a U.S.-based biotechnology platform company that develops microbial protein production systems for industrial, life sciences, food and…
Oramed Pharmaceuticals Inc
ORMP · Pharmaceutical Preparations
Camurus
CAMX · Health Care
Camurus is an international biopharmaceutical company headquartered in Lund, Sweden, focused on developing and commercializing innovative long-acting medicines for severe and chronic diseases.
Advanced Biomed Inc.
ADVB · Services-Medical Laboratories
Galmed Pharmaceuticals Ltd.
EOCN · Pharmaceutical Preparations
Modular Medical, Inc.
MODD · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026